Status:
COMPLETED
CsA vs MMC for Preventing Pterygium Recurrence
Lead Sponsor:
Benha University
Conditions:
Pterygium
Pterygium of the Conjunctiva and Cornea
Eligibility:
All Genders
18-80 years
Phase:
NA
Brief Summary
aimed to compare the efficacy and safety of topical cyclosporin A (CsA) versus mitomycin C (MMC) as adjunctive therapies in preventing pterygium recurrence after surgical excision.
Detailed Description
A total of 40 eyes from 40 patients undergoing pterygium surgery were randomized into two groups: Group A received topical cyclosporin A, while Group B was treated with topical mitomycin C. Ocular sur...
Eligibility Criteria
Inclusion
- Aged 18 years or older.
- Diagnosed with primary pterygium extending at least 1 mm onto the cornea.
- No prior history of pterygium surgery in the affected eye.
Exclusion
- History of ocular surface diseases such as dry eye or Sjögren's syndrome.
- Active ocular infection.
- Known hypersensitivity to CsA or MMC.
- Systemic conditions requiring immunosuppressive therapy.
Key Trial Info
Start Date :
April 1 2024
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 15 2024
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT06944132
Start Date
April 1 2024
End Date
October 15 2024
Last Update
April 25 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ebsar Eye Center
Cairo, Egypt, Egypt, 4450113